{"id":"semaglutide-injection-hd1916","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By activating GLP-1 receptors in the pancreas, semaglutide stimulates the release of insulin and decreases the production of glucagon, a hormone that raises blood sugar levels. This leads to improved glycemic control and weight loss.","oneSentence":"Semaglutide injection works by mimicking the action of a natural hormone in the body called glucagon-like peptide-1 (GLP-1) to help lower blood sugar levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:58.141Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"},{"name":"Weight management in adults with obesity"}]},"trialDetails":[{"nctId":"NCT06161844","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-02-23","conditions":"Type 2 Diabetes Mellitus","enrollment":506},{"nctId":"NCT06604624","phase":"PHASE3","title":"Semaglutide in Treatment of Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2024-09-20","conditions":"Weight Management","enrollment":462}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"semaglutide injection (HD1916)","genericName":"semaglutide injection (HD1916)","companyName":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","companyId":"cspc-zhongqi-pharmaceutical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Semaglutide injection (HD1916) is used to treat Type 2 Diabetes Mellitus and Weight Management, as indicated by ClinicalTrials.gov. The exact mechanism of semaglutide injection (HD1916) is unknown, according to ChEMBL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}